Proposed morphologic classification of prostate cancer with neuroendocrine differentiation

American Journal of Surgical Pathology

Volumn 38, Issue 6, 2014, Pages 756-767

  Epstein, Jonathan I ^a   Amin, Mahul B ^b   Beltran, Himisha ^c   Lotan, Tamara L ^a   Mosquera, Juan Miguel ^c,d   Reuter, Victor E ^e   Robinson, Brian D ^c,d   Troncoso, Patricia ^f   Rubin, Mark A ^c,d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Department of Molecular Biology and Genetics   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

Carcinoid; Large cell neuroendocrine carcinoma; Paneth cell like; Prostate adenocarcinonma; Small cell carcinoma

Indexed keywords

TUMOR MARKER;

ACINAR CELL CARCINOMA; ADENOCARCINOMA; ARTICLE; CARCINOID; CELL DIFFERENTIATION; CHEMISTRY; CLASSIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; MALE; MIXED TUMOR; NEUROENDOCRINE TUMOR; NOMENCLATURE; PANETH CELL; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE TUMOR; SMALL CELL CARCINOMA;

ADENOCARCINOMA; CARCINOID TUMOR; CARCINOMA, ACINAR CELL; CARCINOMA, LARGE CELL; CARCINOMA, SMALL CELL; CELL DIFFERENTIATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS, COMPLEX AND MIXED; NEUROENDOCRINE TUMORS; PANETH CELLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84900836746     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000208     Document Type: Article

References (81)

1. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer. 1999;6:503-519
2. Abrahamsson PA, Wadstrom LB, Alumets J, et al. Peptidehormone-And serotonin-immunoreactive tumour cells in carcinoma of the prostate. Pathol Res Pract. 1987;182:298-307
3. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol. 1993;423:291-294
4. Azzopardi JG, Evans DJ. Argentaffin cells in prostatic carcinoma: Differentiation from lipofuscin and melanin in prostatic epithelium. J Pathol. 1971;104:247-251
5. Kazzaz BA. Argentaffin and argyrophil cells in the prostate. J Pathol. 1974;112:189-193
6. Hirano D, Okada Y, Minei S, et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen Deprivation therapy. Eur Urol. 2004;45:586-592
7. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999;39:135-148
8. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status. Prostate Suppl. 1998;8:18-22
9. Bonkhoff H, Wernert N, Dhom G, et al. Relation of endocrineparacrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate. 1991;19:91-98
10. Xing N, Qian J, Bostwick D, et al. Neuroendocrine cells in human prostate over-express the anti-Apoptosis protein survivin. Prostate. 2001;48:7-15
11. Berruti A, Mosca A, Porpiglia F, et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol. 2007;178: 838-843
12. Mucci NR, Akdas G, Manely S, et al. Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol. 2000;31:406-414
13. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl JMed. 2011; 364:1995-2005
14. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367: 1187-1197
15. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics: Tumors of the Urinary System and Male Genital Organs. WHO Classification of Tumors. Lyon, France: IARC Press; 2004
16. Komiya A, Suzuki H, Imamoto T, et al. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol. 2009; 16:37-44
17. Vashchenko N, Abrahamsson PA. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol. 2005;47:147-155
18. Cohen RJ, Glezerson G, Haffejee Z. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer. Arch Pathol Lab Med. 1992;116:65-66
19. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer. 2005;12:109-117
20. Bostwick DG, Qian J, Pacelli A, et al. Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol. 2002;168:1204-1211
21. Theodorescu D, Broder SR, Boyd JC, et al. Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer. 1997;80:2109-2119
22. Weinstein MH, Partin AW, Veltri RW, et al. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol. 1996;27:683-687
23. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells-A new prognostic parameter in prostate cancer. Br J Urol. 1991;68: 258-262
24. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urology. 2006;68:2-8
25. Casella R, Bubendorf L, Sauter G, et al. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J Urol. 1998;160:406-410
26. Abrahamsson PA, Cockett AT, di Sant'Agnese PA. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl. 1998;8:37-42
27. Allen FJ, Van Velden DJ, Heyns CF. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?. Br J Urol. 1995;75:751-754
28. Ahlgren G, Pedersen K, Lundberg S, et al. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate. 2000;42:274-279
29. Tan MO, Karaoglan U, Celik B, et al. Prostate cancer and neuroendocrine differentiation. Int Urol Nephrol. 1999;31: 75-82
30. Cohen MK, Arber DA, Coffield KS, et al. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer. 1994;74:1899-1903
31. Ishida E, Nakamura M, Shimada K, et al. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer. Pathobiology. 2009;76:30-38
32. Jeetle SS, Fisher G, Yang ZH, et al. Neuroendocrine differentiation Does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch. 2012;461:103-107
33. Aprikian AG, Cordon-Cardo C, Fair WR, et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol. 1994; 151:914-919
34. Aprikian AG, Cordon-Cardo C, Fair WR, et al. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer. 1993;71:3952-3965
35. Weaver MG, Abdul-Karim FW, Srigley J, et al. Paneth cell-like change of the prostate gland A histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol. 1992;16:62-68
36. Tamas EF, Epstein JI. Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol. 2006;30:980-985
37. Adlakha H, Bostwick DG. Paneth cell-like change in prostatic adenocarcinoma represents neuroendocrine differentiation: Report of 30 cases. Hum Pathol. 1994;25:135-139
38. Freschi M, Colombo R, Naspro R, et al. Primary and pure neuroendocrine tumor of the prostate. Eur Urol. 2004;45:166-169
39. Giordano S, Tolonen T, Tolonen T, et al A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Int Urol Nephrol. 2010;42:683-687
40. Goulet-Salmon B, Berthe E, Franc S, et al. Prostatic neuroendocrine tumor in multiple endocrine neoplasia type 2B. J Endocrinol Invest. 2004;27:570-573
41. Whelan T, Gatfield CT, Robertson S, et al. Primary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a child. J Urol. 1995;153:1080-1082
42. Zarkovic A, Masters J, Carpenter L. Primary carcinoid tumour of the prostate. Pathology. 2005;37:184-186
43. Slater D. Carcinoid tumour of the prostate associated with inappropriate ACTH secretion. Br J Urol. 1985;57:591-592
44. Tash JA, Reuter V, Russo P. Metastatic carcinoid tumor of the prostate. J Urol. 2002;167:2526-2527
45. Wasserstein PW, Goldman RL. Primary carcinoid of prostate. Urology. 1979;13:318-320
46. Murali R, Kneale K, Lalak N, et al. Carcinoid tumors of the urinary tract and prostate. Arch Pathol Lab Med. 2006;130:1693-1706
47. Turbat-Herrera EA, Herrera GA, Gore I, et al. Neuroendocrine differentiation in prostatic carcinomas A retrospective autopsy study. Arch Pathol Lab Med. 1988;112:1100-1105
48. Egan AJM, Youngskin TP, Bostwick DG. Mixed carcinoidadenocarcinoma of the prostate with spindle cell carcinoid: The spectrum of neuroendocrine differentiation in prostatic neoplasia. Pathol Case Rev. 1996;1:65-69
49. Lee S, Han JS, Chang A, et al. Small cell-like change in prostatic intraepithelial neoplasia, intraductal carcinoma, and invasive prostatic carcinoma: A study of 7 cases. Hum Pathol. 2013;44: 427-431
50. Almagro UA. Argyrophilic prostatic carcinoma. case report with literature review on prostatic carcinoid and "carcinoid-like" prostatic carcinoma. Cancer. 1985;55:608-614
51. Azumi N, Shibuya H, Ishikura M. Primary prostatic carcinoid tumor with intracytoplasmic prostatic acid phosphatase and prostate-specific antigen. Am J Surg Pathol. 1984;8:545-550
52. Ghali VS, Garcia RL. Prostatic adenocarcinoma with carcinoidal features producing adrenocorticotropic syndrome. immunohistochemical study and review of the literature. Cancer. 1984;54: 1043-1048
53. Ghannoum JE, DeLellis RA, Shin SJ. Primary carcinoid tumor of the prostate with concurrent adenocarcinoma: A case report. Int J Surg Pathol. 2004;12:167-170
54. Stratton M, Evans DJ, Lampert IA. Prostatic adenocarcinoma evolving into carcinoid: Selective effect of hormonal treatment?. J Clin Pathol. 1986;39:750-756
55. Rojas-Corona RR, Chen LZ, Mahadevia PS. Prostatic carcinoma with endocrine features A report of a neoplasm containing multiple immunoreactive hormonal substances. Am J Clin Pathol. 1987;88: 759-762
56. Montasser AY, Ong MG, Mehta VT. Carcinoid tumor of the prostate associated with adenocarcinoma. Cancer. 1979;44:307-310
57. Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Arch Pathol Lab Med. 2004;128:e166-e168
58. Sobin LH, Hjermstad BM, Sesterhenn IA, et al. Prostatic acid phosphatase activity in carcinoid tumors. Cancer. 1986;58: 136-138
59. Wang W, Epstein JI. Small cell carcinoma of the prostate A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32:65-71
60. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate. part I A clinicopathologic study of 20 cases. Cancer. 1987; 59:1803-1809
61. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: An immunohistochemical study. Am J Surg Pathol. 2006; 30:705-712
62. Ro JY, Tetu B, Ayala AG, et al. Small cell carcinoma of the prostate II immunohistochemical and electron microscopic studies of 18 cases. Cancer. 1987;59:977-982
63. Agoff SN, Lamps LW, Philip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238-242
64. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in Distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223
65. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644-648
66. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas.Mod Pathol. 2011;24:820-828
67. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN Deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009;22:1083-1093
68. Guo CC, Dancer JY, Wang Y, et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011;42:11-17
69. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: Evidence supporting monoclonal origin. Mod Pathol. 2011;24:1120-1127
70. Scheble VJ, Braun M, Wilbertz T, et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology. 2010;56:937-943
71. Schelling LA, Williamson SR, Zhang S, et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: The superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum Pathol. 2013;44:2227-2233
72. Deorah S, Rao MB, Raman R, et al. Survival of patients with small cell carcinoma of the prostate during 1973-2003: A populationbased study. BJU Int. 2012;109:824-830
73. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147:935-937
74. Rubenstein JH, Katin MJ, Mangano MM, et al. Small cell anaplastic carcinoma of the prostate: Seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol. 1997;20:376-380
75. Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621-3630
76. Papandreou CN, Daliani DD, Thall PF, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20:3072-3080
77. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer. 2007;14:531-547
78. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487-495
79. Evans AJ, Humphrey PA, Belani J, et al. Large cell neuroendocrine carcinoma of prostate: A clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006;30:684-693
80. Aparicio A, Tzelepi V, Araujo JC, et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate. 2011;71:846-856
81. Mosquera JM, Beltran H, Park K, et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatmentrelated neuroendocrine prostate cancer. Neoplasia. 2013;15:1-10.